Skip to main content
Premium Trial:

Request an Annual Quote

Amgen, Selexis Expand Deal to Include Evaluation of Mammalian Cell Line

NEW YORK (GenomeWeb News) – Amgen expanded an R&D licensing agreement to include the evaluation of Selexis' Sure Cho-M Cell Line.

Under the terms of the deal announced today by Selexis, Amgen will assess the cell line in conjunction with the Selexis SUREtech Vectors for improved R&D. Sure Cho-M Cell Line is a mammalian cell line derived from CHO-K1 cells and is for producing therapeutic recombinant proteins and monoclonal antibodies.

Financial and other terms of the deal were not disclosed.

Today's announcement builds on a relationship between Selexis and Amgen reaching back to 2004, Igor Fisch, president and CEO of Selexis, said in a statement.

"Successful protein expression in R&D is dependent upon a cell line development platform that is robust, high-yielding, and stable," he said. "Selexis is continually optimizing its proprietary cell line and technology platform to enable partners such as Amgen to make better R&D decisions by generating reliable data points faster and more cost efficiently."

Based in Geneva, Selexis provides technologies for drug discovery, cell line development, and scale-up to manufacturing of therapeutic proteins.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.